Overview: HIV-2 Ab TestIntroduction: The HIV-2 Ab Test detects antibodies to HIV-2 to diagnose HIV-2 infection, causing immune deficiency and infections, helping guide antiviral treatment. Affecting 1 in 1,000,000 people in the U.S., HIV-2 poses diagnostic challenges due to its rarity. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses ELISA for high sensitivity, supporting virology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in infectious disease.
Other Names: HIV-2 Antibody Test, HIV-2 Screening Assay.
FDA Status: FDA-approved test, meeting virology standards for diagnostic reliability.
Historical Milestone: HIV-2 testing began in the 1980s with research by Clavel, who identified the virus. ELISA advancements in the 1990s by Abbott improved detection, surpassing earlier Western blot methods.
Purpose: Detects HIV-2 antibodies to diagnose infection, guides antiretroviral therapy, and evaluates patients with recurrent infections, aiming to manage disease.
Test Parameters: HIV-2 antibody levels
Pretest Condition: No special preparation required. Collect serum. Report history of HIV risk factors.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document recurrent infections or HIV risk factors. Include current medications or travel history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., AIDS), and sample collection risks.
Procedural Considerations: Uses ELISA to measure antibodies, requiring labs with plate readers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Positive antibodies confirm HIV-2, guiding therapy. Early treatment might prevent progression, while untreated cases lead to AIDS. Normal levels may require RNA testing.
Specialist Consultation: Consult an infectious disease specialist for interpretation.
Additional Supporting Tests: HIV-2 RNA test, CD4 count, or Western blot to confirm diagnosis.
Test Limitations: Indicates exposure only; correlation with symptoms needed. False negatives possible in early infection.
References: CDC Guidelines, 2023; Science, Clavel F, 2022.
